Lecanemab frequently asked questions resource
By Patti Cullen, CAE | July 28, 2023 | All members
As we have reported in earlier newsletter editions, on January 6, 2023, the Food & Drug Administration (FDA) provided approval for lecanemab (Leqembi) to treat early-stage Alzheimer’s disease. On July 6, 2023, lecanemab was granted full traditional approval by the FDA. Lecanemab is a medication developed by Eisai and Biogen that may help slow the progression of early-stage Alzheimer’s disease. More recently, the Centers for Medicare & Medicaid Services (CMS) approved Medicare to cover the majority of costs of this therapy.
Our partners at the University of Minnesota have compiled several helpful sources into a
frequently asked questions document that may be of help to you in understanding more about this development, but more importantly, will help you respond to questions from residents and family members.
Patti Cullen, CAE | President/CEO |
pcullen@careproviders.org | 952-851-2487